Navigation Links
James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Date:8/6/2013

CUMBERLAND, R.I., Aug. 6, 2013 /PRNewswire/ -- Neurotech Pharmaceuticals, a biotechnology company developing sight-saving therapies for chronic retinal disease, announced today that James Mazzo was appointed the company's Executive Chairman.  Mazzo, a long time leader in the ophthalmic industry, is the former CEO of Abbott Medical Optics (AMO), is an Operating Partner at Versant Ventures and was recently named Chairman and CEO of AcuFocus, a Versant portfolio company.

(Logo: http://photos.prnewswire.com/prnh/20130806/NE59269LOGO)

As Executive Chairman, Mazzo will engage with the Neurotech team to advance the Company's novel technology platform through the clinical development stage toward market availability.

"Neurotech's technology is truly groundbreaking and I am confident it will bring improved therapy to serious retinal diseases such as wet and dry age-related macular degeneration, and macular telangiectasia – diseases that ultimately cause blindness," said James Mazzo.

Neurotech's patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables the continuous delivery of protein drugs directly into the vitreous of the eye.  The Company has demonstrated that a single living ECT implant can treat a diseased retina for two years or more, thereby eliminating the need for monthly injections, the conventional approach to treating retinal disease.  ECT systems can produce all classes of modern biotherapeutic drugs, including peptides, hormones, monoclonal antibodies, antibody fragments and next generation alternative scaffolds.  As a robust technology platform, ECT can be adapted to also generate protein drugs targeting uveitis, glaucoma and other ophthalmic indications.

"I admire Jim's commitment to and extensive accomplishments in the ophthalmic world.  We are honored to have him help lead our company as we advance Neurotech into the next phase of growth," said Ted Danse, President and CEO of Neurotech.

Jim Mazzo's 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold to Abbott Labs in 2009 for $2.8 billion. He was previously with Allergan for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada. He led the spinoff of AMO from Allergan in 2002, expanding the business into a $1 billion industry-leading, publicly-traded corporation. Most recently, he has served as Senior Vice President, Abbott Laboratories and President, Abbott Medical Products.

William J. Link, PhD, Managing Director at Versant Ventures and a Neurotech board member, said, "Jim's talents are tremendously applicable to Neurotech.  We look forward to working together to further Neurotech's promising technology in the treatment of retinal diseases and help people retain their sight."

About Neurotech Pharmaceuticals, Inc.

Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases.  Utilizing its transformational technology, Encapsulated Cell Technology (ECT), Neurotech is developing intraocular implants that provide controlled, sustained and long-term delivery of therapeutic proteins to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease. The Company's lead ECT-based product candidates include NT-503 for the treatment of wet AMD (Phase 2), and Renexus® (NT-501) for the treatment of Macular Telangiectasia (pre-Phase 2).  To learn more, please visit www.neurotechusa.com.


'/>"/>
SOURCE Neurotech USA
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Eurofins MWG Operon, Inc. Names James Corne as Director of Marketing
2. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
4. Tissue Culture Biologicals, Inc. Hires James D. Titus to Lead New Expansion and Branding Development Effort
5. ABC Announces Recipients of James A. Duke Excellence in Botanical Literature Award
6. Dr. James Douglas Adds Human Growth Hormone (HGH) Therapy to IVF Protocols for Poor Responding Patients
7. James bond: A graphene/nanotube hybrid
8. Laureate Biopharma Names James D. Utterback to Board of Directors
9. Herbal Microscopy Book Receives American Botanical Councils James A. Duke Book Award
10. InspireMD Appoints Dr. James Barry to Its Board of Directors
11. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... ... to help the agriculture industry reach its ideal customers with the right message. ... nation. , “As a Midwest company, we realize how crucial the agriculture industry ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... ... August 09, 2017 , ... Okyanos Center for Regenerative Medicine has announced ... Bay Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime event is ... oversight from the Ministry of Health’s National Stem Cell Ethics Committee (NSCEC) and regulations ...
(Date:8/10/2017)... ... August 10, 2017 , ... DrugDev and the Society for ... demonstrate how Good Clinical Practice (GCP) can be used throughout the site activation process ... discuss the importance of GCP compliance, how sites are affected by GCP during selection ...
Breaking Biology Technology:
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):